Effect of Guselkumab (TREMFYA®), a Selective IL-23p19 Inhibitor, on Axial-Related Endpoints in Patients with Active PsA: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years

被引：0

作者：

Mease, Philip ^{[1
,2
]}

Helliwell, Philip S. ^{[3
]}

Gladman, Dafna ^{[4
]}

Poddubnyy, Denis ^{[5
]}

Baraliakos, Xenofon ^{[6
]}

Chakravarty, Soumya ^{[7
,8
]}

Kollmeier, Alexa ^{[9
]}

Xu, Xie ^{[10
]}

Sheng, Shihong ^{[10
]}

Xu, Stephen ^{[10
]}

Shawi, May ^{[11
]}

van der Heijde, Desiree ^{[12
]}

Deodhar, Atul ^{[13
]}

机构：

[1] Swedish Med Ctr, Providence St Joseph Hlth, Seattle, WA USA

[2] Univ Washington, Seattle, WA 98195 USA

[3] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England

[4] Toronto Western Hosp, Schroeder Arthrit Inst, Krembil Res Inst, Toronto, ON, Canada

[5] Charite, Dept Rheumatol, Berlin, Germany

[6] Ruhr Univ Bochum, Rheumazentrum Ruhrgebiet Herne, Herne, Germany

[7] Janssen Sci Affairs LLC, Horsham, PA USA

[8] Drexel Univ, Coll Med, Horsham, PA USA

[9] Janssen Res & Dev LLC, La Jolla, CA USA

[10] Janssen Res & Dev LLC, Spring House, PA USA

[11] Janssen Immunol Global Commercial Strategy Org, Toronto, ON, Canada

[12] Leiden Univ, Dept Rheumatol, Med Ctr, Meerssen, Netherlands

[13] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2021年 / 73卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1330

引用

页码：2760 / 2763

页数：4

共 50 条

[11] Guselkumab, an IL-23 Inhibitor That Specifically Binds to the IL23p19-Subunit, for Active Psoriatic Arthritis: One Year Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Patients Who Were Biologic-Naive or TNFα Inhibitor-Experienced
Ritchlin, Christopher
Helliwell, Philip
Boehncke, Wolf-Henning
Hsia, Elizabeth
Kollmeier, Alexa
Subramanian, Ramanand
Xu, Xie
Sheng, Shihong
Jiang, Yusang
Zhou, Bei
Deodhar, Atul
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[12] EFFICACY AND SAFETY OF GUSELKUMAB, A MONOCLONAL ANTIBODY SPECIFIC TO THE p19-SUBUNIT OF INTERLEUKIN-23, THROUGH 2 YEARS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
Mcinnes, I.
Rahman, P.
Gottlieb, A. B.
Hsia, E. C.
Kollmeier, A.
Xu, X. L.
Sheng, S.
Jiang, Y.
Shawi, M.
Chakravarty, S. D.
Van der Heijde, D.
Mease, P. J.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 783 - 784
[13] Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19-Subunit of Interleukin-23, Through 2 Years: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naive Patients with Active Psoriatic Arthritis
McInnes, Iain
Rahman, Proton
Gottlieb, Alice
Hsia, Elizabeth
Kollmeier, Alexa
Xu, Xie
Sheng, Shihong
Jiang, Yusang
Shawi, May
Chakravarty, Soumya
van der Heijde, Desiree
Mease, Philip
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2777 - 2779
[14] GUSELKUMAB, AN IL-23 INHIBITOR THAT SPECIFICALLY BINDS TO THE IL23P19-SUBUNIT, FOR ACTIVE PSORIATIC ARTHRITIS: ONE YEAR RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PATIENTS WHO WERE BIOLOGIC-NAIVE OR TNF-A INHIBITOR-EXPERIENCED
Ritchlin, C. T.
Helliwell, P.
Boehncke, W. H.
Hsia, E. C.
Kollmeier, A.
Subramanian, R. A.
Xu, X. L.
Sheng, S.
Jiang, Y.
Zhou, B.
Deodhar, A.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1144 - 1145
[15] GUSELKUMAB, AN ANTI-INTERLEUKIN-23P19 MONOCLONAL ANTIBODY, IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: WEEK 24 RESULTS OF THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Mease, Philip J.
Rahman, Proton
Gottlieb, Alice
Hsia, Elizabeth
Kollmeier, Alexa P.
Xu, Xie L.
Subramanian, Ramanand A.
Agarwal, Prasheen
Sheng, Shihong
Zhou, Bei
van der Helide, Desiree
Zazzetti, Federico
McInnes, Lin B.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 23 - 23
[16] Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naive Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study
Mease, Philip J.
Rahman, Proton
Gottlieb, Alice B.
Hsia, Elizabeth
Kollmeier, Alexa
Xu, Xie
Subramanian, Ramanand
Agarwal, Prasheen
Sheng, Shihong
Zhou, Bei
van der Heijde, Desiree
McInnes, Iain
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[17] Efficacy and Safety Results of Guselkumab in Patients with Active Psoriatic Arthritis over 56 Weeks from a Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study
Deodhar, Atul A.
Gottlieb, Alice B.
Boehncke, Wolf-Henning
Dong, Bin
Wang, Yuhua
Zhuang, Yanli
Barchuk, William
Xu, Xie L.
Hsia, Elizabeth
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[18] Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
Deodhar, Atul
Gottlieb, Alice B.
Boehncke, Wolf-Henning
Dong, Bin
Wang, Yuhua
Zhuang, Yanli
Barchuk, William
Xu, Xie L.
Hsia, Elizabeth C.
LANCET, 2018, 391 (10136): : 2213 - 2224
[19] EFFICACY AND SAFETY RESULTS OF GUSELKUMAB, AN ANTI-IL23 MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS OVER 24 WEEKS: A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Deodhar, A.
Gottlieb, A.
Boehncke, W. -H.
Dong, B.
Wang, Y.
Barchuk, W.
Xu, X. L.
Hsia, E.
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 142 - 143
[20] Efficacy and Safety Results of Guselkumab, an Anti-IL23 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis over 24 Weeks: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study
Deodhar, Atul A.
Gottlieb, Alice B.
Boehncke, Wolf-Henning
Dong, Bin
Wang, Yuhua
Barchuk, William
Xu, Xie
Hsia, Elizabeth C.
ARTHRITIS & RHEUMATOLOGY, 2016, 68

← 1 2 3 4 5 →